Participants 68 161 4
intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia
Participants 194 259 3
genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA
Participants 300 526 7
all-trans retinoic acid (ATRA) to chemotherapy for younger patients with nonacute promyelocytic acute myeloid leukemia and high-risk myelodysplastic syndrome, and considered interactions between treatment and molecular markers
Participants 537 576 8
1075 patients less than 60 years of age
